AZD-5312

Main study objectives 1) To determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of ISIS 560131 in Chinese patients with AR V7-positive mCRPC. 2) To preliminarily evaluate the efficacy of ISIS 560131 in Chinese patients with AR V7-positive mCRPC. Secondary study objectives 1) To evaluate the safety and tolerability of ISIS 560131 in patients with AR V7-positive mCRPC; 2) To evaluate the pharmacokinetic characteristics of ISIS 560131 in patients with AR-V7-positive mCRPC; 3) To evaluate the immunogenicity of ISIS 560131; 4) To preliminarily analyze the PK/PD relationship of ISIS 560131 in patients with AR-V7-positive mCRPC. Other research objectives 1) If data permit, analyze AR receptor expression and drug inhibition of signaling pathway regulatory genes; and the consistency of different detection methods for AR-V7; 2) If data permit, characterize the PK characteristics of ISIS 560131 in Chinese AR-V7-positive mCRPC patients based on population pharmacokinetic (PopPK) analysis methods; 3) If data permit, evaluate the relationship between ISIS 560131 exposure in humans and efficacy and adverse events.